However, I noticed that the two US Optogenetic trials for RP by Bionic Sight, using AAV2, & Gensight, using a different AAV have had no troubles, but both are low numbers in low/medium doses. Higher doses still in progress. Good news is they have signs of improved meaningful light sensitivity. Early days.
Ann: Annual Report to shareholders, page-18
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.010(7.69%) |
Mkt cap ! $653.2M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.0¢ | $1.446M | 10.38M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 252759 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 113762 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |